Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned a consensus rating of “Buy” from the sixteen ratings firms that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $61.92.

A number of equities analysts recently commented on the company. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Chardan Capital upped their target price on Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, December 6th. Northland Securities reaffirmed a “buy” rating and issued a $72.00 price target on shares of Esperion Therapeutics in a research note on Friday, November 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $70.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Finally, Cowen initiated coverage on Esperion Therapeutics in a research note on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price target on the stock.

In related news, Director Nicole Vitullo sold 9,326 shares of the stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total transaction of $502,205.10. Following the sale, the director now directly owns 2,472 shares of the company’s stock, valued at $133,117.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 32.50% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Emory University bought a new position in Esperion Therapeutics in the second quarter valued at about $2,164,000. Dimensional Fund Advisors LP lifted its holdings in Esperion Therapeutics by 174.7% in the first quarter. Dimensional Fund Advisors LP now owns 110,475 shares of the biopharmaceutical company’s stock valued at $3,901,000 after acquiring an additional 70,255 shares during the period. Chartwell Investment Partners LLC bought a new position in shares of Esperion Therapeutics in the third quarter worth about $1,374,000. Macquarie Group Ltd. bought a new position in shares of Esperion Therapeutics in the second quarter worth about $1,182,000. Finally, Meditor Group Ltd raised its stake in shares of Esperion Therapeutics by 305.5% in the third quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after buying an additional 1,728,935 shares during the period. 92.28% of the stock is currently owned by institutional investors.

Shares of Esperion Therapeutics (ESPR) traded up $1.05 during mid-day trading on Friday, reaching $57.13. The company’s stock had a trading volume of 340,633 shares, compared to its average volume of 1,014,400. Esperion Therapeutics has a 12-month low of $10.71 and a 12-month high of $65.20.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the previous year, the company posted ($0.77) earnings per share. equities research analysts forecast that Esperion Therapeutics will post -7.3 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with's FREE daily email newsletter.